![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
| Item Type: | Article |
|---|---|
| Title: | No significant effect of orally administered chemokine receptor 1 antagonist on intercellular adhesion molecule-3 expression in relapsing--remitting multiple sclerosis patients |
| Creators Name: | Reuss, R., Schreiber, V., Klein, A., Infante-Duarte, C., Filippi, M., Pabst, W., Pohl, C. and Oschmann, P. |
| Abstract: | We investigated the expression of intercellular adhesion molecules ICAM-1 and ICAM-3 on peripheral blood mononuclear cells in a subgroup of 34 patients with relapsing-remitting multiple sclerosis who were treated orally with the chemokine receptor 1 antagonist BX 471 in a 16-week, randomised, double-blind, placebo-controlled phase II study. ICAM-1 and ICAM-3 expression was measured by flow cytometry at different time points during and after therapy and compared using multivariate analysis of variance and non-parametric Mann Whitney test. ICAM-3 expression on CD14( +) peripheral blood mononuclear cells was increased in the verum group under therapy, but did not differ significantly between the verum and placebo groups. Most likely, this trend represents a small epiphenomenon only mediated by receptor cross-talk and feedback mechanisms. |
| Keywords: | Chemokine Receptor 1 Antagonist, Flow Cytometry, Intercellular Adhesion Molecule-3, MRI, Multiple Sclerosis, Receptor Cross-Talk |
| Source: | Multiple Sclerosis |
| ISSN: | 1352-4585 |
| Publisher: | Sage Publications |
| Volume: | 16 |
| Number: | 3 |
| Page Range: | 366-369 |
| Date: | March 2010 |
| Official Publication: | https://doi.org/10.1177/1352458509358188 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
